Neximmune Stock Price To Sales
NEXIDelisted Stock | USD 2.43 0.22 9.95% |
Neximmune fundamentals help investors to digest information that contributes to Neximmune's financial success or failures. It also enables traders to predict the movement of Neximmune Pink Sheet. The fundamental analysis module provides a way to measure Neximmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neximmune pink sheet.
Neximmune |
Neximmune Company Price To Sales Analysis
Neximmune's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Neximmune has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Neximmune Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neximmune's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neximmune could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics of similar companies.Neximmune is currently under evaluation in price to sales category among its peers.
Neximmune Fundamentals
Return On Equity | -1.96 | ||||
Return On Asset | -0.7 | ||||
Current Valuation | (491.95 K) | ||||
Shares Outstanding | 1.37 M | ||||
Shares Owned By Insiders | 17.00 % | ||||
Shares Owned By Institutions | 11.17 % | ||||
Number Of Shares Shorted | 15.99 K | ||||
Price To Book | 1.38 X | ||||
EBITDA | (28.17 M) | ||||
Net Income | (32.34 M) | ||||
Cash And Equivalents | 53.13 M | ||||
Cash Per Share | 2.20 X | ||||
Total Debt | 68.81 K | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 6.54 X | ||||
Book Value Per Share | 2.00 X | ||||
Cash Flow From Operations | (31.43 M) | ||||
Short Ratio | 2.26 X | ||||
Earnings Per Share | (24.11) X | ||||
Target Price | 2.0 | ||||
Beta | 1.94 | ||||
Market Capitalization | 3.25 M | ||||
Total Asset | 8.59 M | ||||
Retained Earnings | (222.59 M) | ||||
Working Capital | 316.73 K | ||||
Net Asset | 8.59 M |
About Neximmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neximmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neximmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neximmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |